Table 1.
The Baseline Characteristics of Examined Patients
| Group 1 (n = 20) | Group 2 (n = 7) | Group 3 (n = 10) | |
|---|---|---|---|
| Male | 16 (80) | 7 (100) | 8 (80) |
| Age, y | 71 ± 16 | 54 ± 17 | 65 ± 13 |
| Weight, kg | 85.7 ± 17.6 | 84.1 ± 9.9 | 85.6 ± 13.1 |
| BMI, kg/m2 | 29 ± 6 | 26 ± 2 | 29 ± 5 |
| BMI range, kg/m2 | 20-38 | 24-30 | 24-38 |
| Systolic blood pressure, mm Hg | 127 ± 29 | 129 ± 25 | 143 ± 28 |
| Left ventricle ejection fraction, % | 41 ± 16 | 29 ± 13 | 51 ± 13 |
| Blood count | |||
| Hemoglobin, g/dL | 11.7 ± 2.6 | 14.7 ± 1.0 | 14.7 ± 1.2 |
| Hematocrit, % | 36.6 ± 7.1 | 44.3 ± 3.8 | 44.1 ± 3.2 |
| White blood cells, 10 × 3/μL | 7.4 ± 2.6 | 6.8 ± 2.4 | 7.4 ± 1.5 |
| Platelets, 10 × 3/μL | 215 ± 72 | 250 ± 75 | 202 ± 38 |
| Biochemistry | |||
| Serum Na+, mmol/L | 142 ± 4 | 141 ± 1 | 140 ± 2 |
| Creatinine, mg/dL | 1.41 ± 0.37 | 1.03 ± 0.19 | 0.84 ± 0.16 |
| Urea, mg/dL | 72 ± 43 | 26 ± 6 | 35 ± 12 |
| NT-proBNP, pg/mL | 5,438 (4,008-10,808) | 2,054 (1,801-2,317) | 396 (112-1,994) |
| Pharmacological treatment | |||
| Beta blockers | 16 (80) | 7 (100) | 5 (50) |
| Aldosterone receptor antagonists | 10 (50) | 5 (71) | 4 (40) |
| SGLT2 inhibitors | 11 (55) | 1 (14) | 2 (20) |
| Angiotensin-converting enzyme inhibitors | 14 (70) | 4 (57) | 7 (70) |
| Sacubitril/valsartan | 2 (10) | 1 (14) | 0 (0) |
Values are n (%), mean ± SD, or median (Q1-Q3), unless otherwise indicated.
BMI = body mass index; NT-proBNP = N-terminal pro–B-type natriuretic peptide; SGLT2 = sodium glucose cotransporter 2.